Ultragenyx Pharmaceutical (RARE) EBITDA (2013 - 2026)

Ultragenyx Pharmaceutical (RARE) has 14 years of EBITDA data on file, last reported at -$169.0 million in Q1 2026.

• On a quarterly basis, EBITDA fell 18.18% year-over-year to -$169.0 million in Q1 2026; TTM through Mar 2026 was -$561.1 million, a 9.23% decrease from a year earlier, with the FY2025 full-year figure at -$535.0 million, changed 0.19% from the prior year.
• EBITDA for Q1 2026 stood at -$169.0 million, down from -$113.3 million in the prior quarter.
• Over the last five years, EBITDA for RARE reached as high as -$107.9 million in Q2 2025 and fell as low as -$225.1 million in Q3 2022.
• Historically, EBITDA has averaged -$144.6 million across 5 years, with a median of -$143.0 million in 2025.
• Across the five-year window, EBITDA tumbled 150.55% in 2022 and jumped 35.53% in 2023, its largest moves.
• Year by year, EBITDA stood at -$145.6 million in 2022, then increased by 16.33% to -$121.8 million in 2023, then fell by 0.38% to -$122.3 million in 2024, then increased by 7.38% to -$113.3 million in 2025, then tumbled by 49.18% to -$169.0 million in 2026.
• Per Business Quant data, the three most recent EBITDA figures were -$169.0 million in Q1 2026, -$113.3 million in Q4 2025, and -$170.9 million in Q3 2025.